A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
Clinical trial NCT04259281 · COMPLETED
Trial details
- NCT number
- NCT04259281
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-24
- Primary completion
- 2025-01-08
- Enrollment
- 74
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.